Navigation Links
Rheumatoid Arthritis Therapeutics in Thailand
Date:4/6/2009

BANGKOK, April 6 /PRNewswire/ -- Rheumatoid arthritis (RA) is a systemic disease or an autoimmune disorder in which the body's defense system attacks the joints through the thin layer of cells called the synovium that lines and lubricates the joints. The most visible symptoms of RA are swollen joints and crippling stiffness, particularly of the hands and feet. It can cause fatigue, fever, loss of appetite and also impedes mobility and quality of life. RA cannot be confirmed or excluded by one single test. The diagnosis of RA is based on clinical examination of symptoms, patient history, blood tests, rheumatoid factor (RF), anti-cyclic citrullinated peptide (Anti-CCP), and X-ray.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Rheumatoid arthritis (RA) is a relatively less common inflammatory arthritis, affecting about 4 per 1,000 individuals in Thailand. About four times as many women as men have the disease. Most of the patients fall between 30 to 40 years of age. In 2008, it is estimated that about 300,000 people with RA have been diagnosed and treated. In the absence of readily available studies to evaluate the prevalence and incidence of RA in Thailand, the prevalence is estimated to be approximately 0.4 percent. Incidence is assumed to be fairly close to the prevalence figures, as the disease is not common and new cases are not likely to impact the prevalence significantly. The incidence is likely to increase with the increase in awareness of the disease among both physicians as well as the population, and with the early diagnosis of the disease. Currently, physicians see more of moderate to severe cases, and in the future expect to tap patients in early stages, so as to prevent disability.

Frost & Sullivan, Research Analyst Sushma Rajan says, "The diagnosis of RA is based on clinical examination of symptoms, patient history, as well as some blood tests. RA cannot be confirmed or excluded by any one test. The most common test is rheumatoid factor (RF). The other supporting tests are: anticyclic citrullinated peptide (Anti-CCP), erythrocyte sedimentation rate (ESR), and X-ray."

"Recent work productivity studies have confirmed that better disease awareness and availability of treatment options have resulted in fewer patients ceasing to work and more patients reporting lower impact of their disease on work as well as family and social activities," she further elaborates.

Methotrexate (MTX), a DMARD (disease-modifying anti-rheumatic drugs) has been traditionally used to treat RA. It is also the most used form of treatment in rheumatoid arthritis, especially with generic forms available. Currently, combination therapies between DMARDs and NSAIDs (non-steroidal antiinflammatory drugs) are commonly practiced.

DMARDs capture the majority of the RA therapeutics market owing to the availability of reimbursement for treatment with these drugs and their easy availability over the counter. DMARDs are expected to retain majority share in the forecast period as well.

According to Rajan, "Biologics are used in combination with DMARDs for moderate to severe RA patients. Some biologic drugs are currently reimbursed, if treated in government hospitals. Physicians opine that with more drugs brought into the hospital formularies, the usage of biologics would increase for treatment earlier in the disease."

Physicians consider the efficacy of medication and minimum side effects to be the key factors while considering the choice of treatment for RA patients.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

    Contact:
    Emmie Kaur
    Corporate Communications - Healthcare, Asia Pacific
    DID: +603 6204 5913
    Email: emmie.kaur@frost.com

    Jasminder Kaur
    Corporate Communications - Healthcare, Australia
    DID: +65 6890 0937
    Email: jkaur@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Biologic treatment for rheumatoid arthritis and the risk of cancer
2. Genes Boost Risk for Rheumatoid Arthritis, Lupus
3. The genes involved in rheumatoid arthritis identified
4. Genome Area Linked to Rheumatoid Arthritis
5. Meditation therapy for rheumatoid arthritis patients
6. Meditation May Help Rheumatoid Arthritis Sufferers
7. Researchers identify genes that increase rheumatoid arthritis risk
8. The widening mortality gap between people with rheumatoid arthritis and the general population
9. Rheumatoid Arthritis Death Rate Unchanged
10. Drugs Can Ease Juvenile Rheumatoid Arthritis
11. Rheumatoid Arthritis Boosts Heart Disease Threat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... Colorado spine surgeon, ... of 334 spine surgeons to know in 2016 . The list consists of ... of spine surgery. , Dr. Corenman understands the importance of clinical excellence; he ...
(Date:2/11/2016)... ... February 11, 2016 , ... Dickinson Insurance & Financial Services continues their commitment ... in support of a local boy named Barrett, who has been fighting ALL leukemia ... and rally support for, all local families dealing with childhood cancer. Information on how ...
(Date:2/11/2016)... ... February 11, 2016 , ... From March ... Academy of Dermatology Annual Meeting at the Walter E. Washington Convention Center in ... for both the condition of hyperhidrosis (excessive sweating) and its treatment options. Specifically, ...
(Date:2/11/2016)... ... ... The book, “Computers Should Just Work!”, provides a basic, non-techie education on how ... signing a contract and how to spot an incompetent or dishonest IT person before ... and technology, it’s more important than ever to make sure the company you outsource ...
(Date:2/10/2016)... ... February 10, 2016 , ... The 9th ... Molecular Imaging Congress (WMIC), will be held in New York City, NY on ... Biology…Improving Therapy.” The congress will highlight and emphasize how imaging reveals a greater ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... -- Indiso ltd , a medical technology company ... respiratory diseases announced today positive results in its clinical ... patients show improvements in respiratory functions and other clinical ... Upper and lower respiratory tract diseases and allergy ... reached epidemic level. Increasing number of studies however show ...
(Date:2/10/2016)... http://www.researchandmarkets.com/research/rp4pg8/molecular ) has ... Diagnostics Reports Bundle" report to their ... announced the addition of the "Molecular ... offering. --> Research and Markets ... of the "Molecular Diagnostics Reports Bundle" ...
(Date:2/10/2016)...  Cepheid (Nasdaq: CPHD ) today announced ... President and Chief Operating Officer, has been promoted ... Officer.  In his new capacity, Mr. Kocmond,s responsibilities ... Operations in addition to Manufacturing Operations, Engineering, Technical ... to report to John Bishop , Cepheid,s ...
Breaking Medicine Technology: